顺铂联合吉西他滨或紫杉醇对晚期肺鳞癌的疗效评价  

Efficacy of cisplatin with gemcitabine or paclitaxel in advanced lung squamous cell carcinoma

作　　者：罗海清[1] 官成浓[1] 梁亚海[1] 王镇南[1] 周和超[1] 余忠华[1] 

机构地区：[1]广东医学院附属医院肿瘤中心二区,广东湛江524001

出　　处：《广东医学院学报》2012年第2期132-134,共3页Journal of Guangdong Medical College

摘　　要：目的观察吉西他滨联合顺铂和紫杉醇联合顺铂对晚期肺鳞癌的疗效差异。方法 78例病理确诊的Ⅲb~Ⅳ期肺鳞癌患者随机分为GP组和TP组,分别采用吉西他滨联合顺铂、紫杉醇联合顺铂治疗,每组39例。21 d为1个周期,至少接受4个周期化疗,每2个周期通过胸部CT评价疗效。结果 GP组和TP组中位生存期分别为11.6个月和10.1个月,1a生存率分别为53.8%和30.8%,差异有统计学意义(P<0.05);临床获益率分别为33.3%和28.2%,疾病控制率分别为79.4%和76.9%,差异无统计学意义(P>0.05)。结论 GP与TP方案治疗晚期肺鳞癌疗效相当,但GP方案可获得更高的中位生存期和1 a生存率。Objective To compare the efficacy of gemcitabine with cisplatin（GP） and paclitaxel with cisplatin（TP） in advanced lung squamous cell carcinoma（SCC）.Methods Seventy-eight patients with stage IIIb^IV lung SCC were divided into GP and TP groups,receiving GP and TP regimen,respectively.All patients were treated with at least four 21-day courses,and evaluated by chest CT every two courses.Results The median survival time were 11.6 months and 10.1 months,and 1-year survival rates were 53.8% and 30.8% in GP and TP groups,respectively,and the difference was significant between both groups（P〈0.05）.The clinical benefit rates（CR＋PR） were 33.3% and 28.2%,and disease control rates（CR＋PR＋SD） were 79.4% and 76.9% in GP and TP groups,respectively,and the difference was insignificant between both groups（P〉0.05）.Conclusion The efficacy of GP and TP regimen is similar for patients with advanced lung SCC,but GP regimen can further improve the median survival time and 1-year survival rate.

关 键 词：吉西他滨 紫杉醇 顺铂 肺癌 

分 类 号：R730.53[医药卫生—肿瘤] R734.2[医药卫生—临床医学]